This article is more than 5 years old. Information may no longer be current.

Use of Ligand-Inducible Autologous T-cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors

Issue: December 2018 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1/2 study looking to evaluate the safety and activity of BPX-601 in previously treated advanced solid tumors (gastric, pancreatic or prostate) expressing high levels of prostate stem cell antigen (PSCA). T-cells from the participants are modified to recognize and target the PSCA tumor marker on the cancer cells.